12
Complimentary Report Sample Learn more at www.fwreports.com/asco-2014 Cover photo: © lily – Fotolia.com
Complimentary Report Sample
Learn more at www.fwreports.com/asco-2014
Cover photo: © lily – Fotolia.com
2
Overarching objective:
• To understand physicians’ perceptions and opinions about information presented at the
American Society of Clinical Oncology Annual Meeting, held in Chicago, IL., May 30 to
June 3, 2014 (hereinafter ASCO 2014), and to assess how this information may impact
treatment landscape and physician’s future practice
Key issues and themes explored during the research:
• General perception and impact of information in three key areas; (1) cancer
immunotherapy (IO); (2) breast cancer (BC); and (3) non-small-cell lung cancer (NSCLC)
• Perceived value and impact of key abstracts across the same three key areas,
physicians’ outlook and concerns of the future of each key area and future usage
intentions of current and pipeline products
Research Aims and Objectives
3
Survey Methodology
Primary research:
• Respondents (n=100 respondents; n=71medical oncologists; n=29 haematologists) were
screened to ensure that they attended ASCO 2014, spent at least 50% of their time attending
the presentation and poster sessions and spent time in IO, breast cancer and NSCLC sessions.
Respondents were also selected based on patient load (had to see at least 10 patients each for
NSCLC and breast cancer, and see at least total of 100 patients, been in active practice
between 5-35 years and devote at least 50% time in direct patient care. Only US-based
physicians were included in the research.
Timings:
• Launched within a week of ASCO 2014 finishing, with fieldwork running until July 2, 2014
Fielding:
• Data was collected via a 20-minute internet-based questionnaire
• All physicians were paid an incentive to take part in the survey
4
Full Report Table of Contents
5
Time Spent at the ASCO Conference and Patient Load
On average, the recruited physicians spent half of their time attending sessions on breast cancer,
immunotherapy and NSCLC, and see 40% of their patients for breast cancer and NSCLC
Base: All physicians (100)
S.6 At this year’s ASCO meeting, what percent of time did you spend in the sessions that focus on each of the following areas? S.8 Thinking about your
patients who have been diagnosed with solid tumours, how many patients diagnosed with each of the following tumour types do you see/treat in a typical
month?
20
16
15 14
12
11
10 2
Breast cancerImmunotherapyNon-small cell lung cancer (NSCLC)Gastrointestinal cancerLeukemia, myelodysplasia, and transplantationGenitourinary cancerMelanoma/skin cancerOther
22
17
16
9
8
28
Breast cancer
Non-small cell lungcancer (NSCLC)
Colorectal cancer
Metastatic Melanoma
Renal cell carcinoma(RCC)
All other types
% of time % of patients
Percentage of time spent at ASCO in each area
Patient load by tumour type
Total patients seen in a typical month
277
See appendix for ungrouped ranking of all abstract sessions
6
Most Important Information; Immunotherapy
When unprompted, close to half of the physicians recall “Information on PD-1/PD-L1 inhibitors” to
be the most important information they saw/heard in the area of immunotherapy
Overall
Base 100
Information on specific medications (net) 62%
Information on PD-1/PD-L1 Inhibitors 47%
• Information on PD-1/PD-L1 Inhibitors 26%
• Use of PD-1/PD-L1 inhibitors in melanoma 9%
• Use of PD-1 inhibitors in lung cancer/non-small cell lung cancer (NSCLC) 7%
• Use of PD-1/PD-L1 inhibitors in various cancer types/multiple malignancies 5%
• Information on PD-1+ipilimumab combo 3%
• Information on nivolumab 3%
• Information on nivolumab+Yervoy combo 3%
Information on Yervoy (ipilimumab) 5%
Updates on immune checkpoint inhibitors 4%
Information on vaccine therapies 3%
Updates on clinical data on different indications (net) 23%
Updates on melanoma data 18%
Updates on lung cancer data 6%
Information on new drugs/treatment options (net) 20%
Information on new/novel upcoming treatment options 16%
Information on new medications for melanoma 4%
Information on mechanism of action 4%
None 3%
DK/NA 5%
Legend: Highest –Directional
Base: All physicians
Q.105: What is the most important information you recall hearing or seeing at the ASCO 2014 conference in each of the following areas?
7
Overall
Base 100
Information on specific medications (net) 41%
Information on HER2 inhibitors 11%
• Information on Perjeta (pertuzumab) 5%
• Information on lapatinib 5%
Information on Zoladex (goserelin) 9%
Information on Aromatase inhibitors (AIs) 8%
• Information on Aromatase inhibitors (AIs) 4%
• Information on Aromasin (exemestane) 4%
Information on tamoxifen 4%
Information on cyclin dependent kinase (CDK) inhibitor 3%
Updates on clinical data (net) 28%
Results of ALTTO clinical trial 11%
Data on ovarian suppression 6%
Results of PARP trials 4%
Information on new drugs/treatment options (net) 23%
Information on new/novel upcoming treatment options 10%
Information on new treatment for HER2-positive breast cancer 6%
Information on new targeted therapy options 3%
Information on use of medication under specific application settings (net) 11%
Application on specific patient types 8%
• Use of aromatase inhibitors (AIs) on premenopausal patients 3%
None 6%
DK/NA 4%
Most Important Information; Breast Cancer
In terms of breast cancer, physician opinions are more varied compared to immunotherapy, with
information on HER2 inhibitors and ALTTO trial mentioned slightly more
Legend: Highest –Directional
Base: All physicians
Q.105: What is the most important information you recall hearing or seeing at the ASCO 2014 conference in each of the following areas?
8
Most Important Information; NSCLC
Given the promising application of immunotherapy in NSCLC, close to 1/3rd physicians recalled
“Information on PD-1/PD-L1 inhibitors” to be the most important information on NSCLC
Legend: Highest –Directional
Overall
Base 100
Information on specific medications (net) 50%
Information on PD-1/PD-L1 Inhibitors 26%
• Information on PD-1/PD-L1 Inhibitors 23%
• Information on nivolumab 3%
Information on ramucirumab 12%
• Information on ramucirumab 10%
Information on ALK inhibitors 8%
• Information on ALK inhibitors 6%
• Information on Zykadia(ceritinib) 3%
Information on TKI Inhibitors 7%
Information on EGFR inhibitors 4%
Information on new drugs/treatment options (net) 22%
Information on new/novel upcoming treatment options 14%
Information on new targeted therapy options 7%
Information on use of medications under specific settings (net) 14%
Use of docetaxel+ramucirumab combo in 2nd line therapy 3%
Use of Tarceva +/- Avastin for patients with EGFR mutant advanced NSCLC 3%
Use of Tyrosine-kinase inhibitor (TKI) for patients with EGFR mutant 3%
Updates on clinical data 6%
Improvement in overall survival (OS)/progression free survival (PFS) 3%
None 6%
DK/NA 4%
Base: All physicians
Q.105: What is the most important information you recall hearing or seeing at the ASCO 2014 conference in each of the following areas?
9
Base: All physicians
Q100: How valuable to you was attending the ASCO 2014 conference in each of the following areas?
On average, half of the physicians (more for immunotherapy and less for NSCLC) indicated that
attending ASCO 2014 was “very” or “extremely” valuable for them in all three areas, with
information on immunotherapy being the most valuable
Perceived Value of Information from ASCO 2014
Immunotherapy, Breast Cancer, and NSCLC
31
15
14
36
31
38
28
48
41
5
6
6 1
Immunotherapy
Non-small celllung cancer
(NSCLC)
Breast cancer
Extremely Valuable Very valuable Moderately valuable
Slightly valuable Not at all valuable
% of respondents
Mean
3.9
3.6
3.6
Legend: Highest
10
23
15
13
40
38
31
27
33
46
8
13
6
2
1
4
New informationon
Immunotherapy
New informationon Non-small cell
lung cancer(NSCLC)
New informationon Breast cancer
Extreme impact Significant impact Moderate impact Slight impact No impact
Similarly, physicians indicated new information on immunotherapy is likely to have the most
impact on their treatment practice over the next 3 years
Perceived Impact of Information from ASCO 2014
Immunotherapy, Breast Cancer, and NSCLC
% of respondents
Legend: Highest
Base: All physicians
Q110: What level of impact do you expect the new information you received at ASCO 2014 in each of the following areas will have on your treatment practices over the next 3 years?
Mean
3.7
3.5
3.4
FirstWord is an innovative industry intelligence leader serving over 200,000 Pharma
and MedTech professionals worldwide.
FirstWord Reports deliver insights, analysis and expert views on pharma industry
issues and topics.
FirstWord FirstView reports provide clients with data, expert opinion and insight on
critical market shaping issues and changes in the pharma industry's operating
environment. With leading market research capabilities and expertise, a 1-million
strong online physician community, FirstView's insights and analysis are 'must read'
for industry professionals seeking to understand future pharma market dynamics.
Learn more at www.fwreports.com.
FirstWord Therapy Trends reports deliver a deep level of insight into the
market impact of current and future therapies for the treatment and diagnosis of major
medical conditions. These unbiased and continuously updated FirstWord research
reports are delivered in two modules: KOL Insight and Consensus Outlook.
Learn more at www.fwreports.com.
FirstWord Dossier reports provide insight and the latest thinking based on
numerous interviews with industry experts. Covering important trends and the most
challenging issues affecting the pharmaceutical industry today, these highly-focused
actionable intelligence reports deliver information vital for competitive advantage.
Learn more at www.fwreports.com.
FirstWord Pharma Plus is a personalised
and comprehensive intelligence service
delivering up-to-the-minute pharma news,
insight, analysis and expert views of importance
to your company’s success.
Subscribe today at www.firstwordpharma.com
FirstWord Medtech Plus is a personalised and
comprehensive intelligence service reporting
on the latest news and developments for the
Medical technology and diagnostic industries.
Subscribe today at www.firstwordmedtech.com/
Stay Connected
www.fwreports.com/asco-2014
www.fwreports.com
www.firstwordgroup.com
US: +1 212 220 0880
UK: +44 (0) 20 7665 9240
Contact Us
.
For more information
